JPRN-jRCT2071230063招募中1 期
ONO-1110-02:Open-label Phase 1 study to Evaluate Target Molecule Occupancy in the Brain of ONO-1110 by PET imaging Using ONO-SE-853(18F) in Healthy Japanese Adult Males.
Osawa Masahiro0 个研究点目标入组 40 人开始时间: 2023年9月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 45age old（—）
入选标准
- •1) Japanese healthy adult male subjects
- •2) Age at the time of informed consent: 18 to 45
- •3) BMI (at screening): 18.5 kg/m2 to less than 30.0 kg/m2
排除标准
- •1) Subjects who are on a treatment for or with a history of respiratory, cardiovascular, psychiatric, neurologic, gastrointestinal, immunologic, hepatic, renal, hematopoietic or endocrine and/or other disease.
- •2) Subjects with current or with a history of severe allergy to drugs or foods
- •3) Subjects with current or with a history of drug or alcohol abuse
研究者
相似试验
已完成
1 期
Study to evaluate the amount of ketoprofen remaining in the mouth and its concentration in saliva after mouthwash rinse with OKI gola® 1.6% collutorio in healthy male and female volunteersPhase I study in healthy volunteers of both sexesISRCTN14847288Dompé farmaceutici S.p.A.36
进行中（未招募）
1 期
A study to evaluate lucitanib in combination with nivolumab in patients with a solid tumorEUCTR2019-002980-81-DEClovis Oncology, Inc.161
进行中（未招募）
1 期
A study to evaluate lucitanib in combination with nivolumab in patients with a solid tumorEUCTR2019-002980-81-ATClovis Oncology, Inc.161
进行中（未招募）
1 期
A study to evaluate lucitanib in combination with nivolumab in patients with a solid tumorAdvanced gynecological solid tumorMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2019-002980-81-ITCLOVIS ONCOLOGY, INC161
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaCD1d-positive relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-ESAVA Therapeutics B.V.102